EmbryoTrans Biotech ApS
APSDissolvedAdvertising protectionCVR 36701676Sommervænget 2, 3390 HundestedRetail sale of medical and orthopaedic goods· NACE 4774Est. 2015 · 11 years old1 employees
Loading company…
Overview
EmbryoTrans Biotech ApS is a Danish APS based in Hundested, operating in the Retail sale of medical and orthopaedic goods sector. Incorporated in 2015, the company has 1 employee and reported a gross profit of DKK 520.0k in its latest annual filing.
Gross profit 2020
520K DKK
−61% vs 2019
EBITDA margin (of gross profit)
−1.2 %
−114% vs 2019
Net profit 2020
-10.4K DKK
-145% vs 2019
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
67.7 %
StrongAmong the 30% highest rated companies in the industry
20162020
Liquidity ratioCurrent assets ÷ Short-term debt
3.1×
StrongAmong the 30% highest rated companies in the industry
20162020
Return on assets (ROA)Net profit ÷ Total assets × 100
-2.9 %
WeakAmong the 40% lowest rated companies in the industry
20162020
EBITDA — year on year
DKK thousandsKey figures
Annual report 2020| Gross profit | 520K DKK | -61% |
| EBITDA | -6.1K DKK | -114% |
| Net profit | -10.4K DKK | -145% |
| Total assets | 358.2K DKK | -28% |
| Equity | 242.3K DKK | -4% |
| Employees | 1 | — |
Company information
Legal name
EmbryoTrans Biotech ApS
CVR number
36701676
Legal form
Anpartsselskab
NACE code
Founded
22 March 2015 · 11 years
Share capital
DKK 50,000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2020-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af én direktør eller af den samlede bestyrelse.
Contact
Address
Sommervænget 2, 3390 Hundested
Advertising protection
Active — opted out of marketing use
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2020), EmbryoTrans Biotech ApS reported a gross profit of DKK 520.0k, a decrease of 61% on the year before. The figures on this page draw on 5 annual filings covering 2016 to 2020. The bottom line showed a net loss of DKK 10.4k, and the EBITDA margin stood at -1.2%.
At the end of 2020, equity financed 67.7% of the balance sheet, and current assets covered short-term debt 3.1 times.
Financials
Gross profit
DKK thousandsEBITDA
DKK thousandsIncome statement
DKK thousands| Item | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|
| Gross profit | 520 | 1,320 | 1,136 | 1,838 | 1,767 |
| Staff expenses | -526 | -1,277 | -1,144 | -1,597 | -1,585 |
| EBITDA | -6 | 43 | -8 | 242 | 182 |
| Depreciation & amort. | -1 | -4 | -4 | -4 | -4 |
| EBIT | -7 | 38 | -12 | 237 | 178 |
| Net financials | -0 | -4 | -2 | -5 | -3 |
| Profit before tax | -8 | 35 | -15 | 232 | 175 |
| Tax | 3 | 11 | 3 | 60 | 43 |
| Net profit | -10 | 23 | -18 | 172 | 132 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
DKK thousands| Item | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|
| Total assets | 358 | 498 | 745 | 1,270 | 838 |
| Equity | 242 | 253 | 260 | 377 | 455 |
| Long-term debt | 0 | 6 | 0 | 0 | 0 |
| Short-term debt | 116 | 239 | 486 | 893 | 379 |
| Total debt | 116 | 245 | 486 | 893 | 379 |
Financial ratios
5-year trendEBITDA margin (of gross profit)
-1.2 %
20162020
Equity ratio
67.7 %
StrongAmong the 30% highest rated companies in the industry
20162020
Return on equity
-4.3 %
WeakAmong the 30% lowest rated companies in the industry
20162020
Net profit margin (of gross profit)
-2.0 %
20162020
Asset turnover (of gross profit)
1.45×
20162020
Debt / equity
0.48×
StrongAmong the 40% highest rated companies in the industry
20162020
Sector performance
23 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Return on equity (ROE)Weak
Among the 30% lowest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Weak
Among the 40% lowest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Weak
Among the 30% lowest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Weak
Among the 40% lowest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioWeak
Among the 30% lowest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Gross marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Liquidity
Current ratioStrong
Among the 30% highest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioVery strong
Among the 20% highest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioVery strong
Among the 20% highest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityAverage
Around the average of companies in the same industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalVery strong
Among the 10% highest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioVery weak
Among the 20% lowest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioStrong
Among the 30% highest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioStrong
Among the 30% highest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityStrong
Among the 40% highest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityStrong
Among the 40% highest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtWeak
Among the 30% lowest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtWeak
Among the 30% lowest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageWeak
Among the 30% lowest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtAverage
Around the average of companies in the same industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginWeak
Among the 40% lowest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Equity to contributed capitalAverage
Around the average of companies in the same industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityWeak
Among the 40% lowest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtVery strong
Among the 10% highest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Asset turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Annual reports & filings
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|
Former (1)
LB Management | Management | 2015 – 2022 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|
Former (4)
TH Chairman | Chairman | 2015 – 2015 |
LB Board of Directors | Board of Directors | 2016 – 2022 |
BJ Board of Directors | Board of Directors | 2015 – 2015 |
UB Chairman | Chairman | 2016 – 2022 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Individual | 10–14.99% | 10–14.99% | 2015 | |
| Company | 66.67–89.99% | 66.67–89.99% | 2015 | |
| Company | 33.33–49.99% | 33.33–49.99% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
STROEBECH CONSULT HOLDING ApS
EmbryoTrans Biotech ApS (this company)Board network connections
Board members of EmbryoTrans Biotech ApS also hold positions in 17 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bjarne Jørnsgård | Board of Directors | 6 companiesMany roles |
| Lotte Bjørg Strøbech | Management | 5 companies |
| Trine Hastrup | Chairman | 5 companies |
| Ulrik Bangsbo Hansen | Chairman | 1 company |
Frequently asked questions
What is the CVR number of EmbryoTrans Biotech ApS?
EmbryoTrans Biotech ApS is registered with CVR / Virk under CVR 36701676.
What is the gross profit of EmbryoTrans Biotech ApS?
EmbryoTrans Biotech ApS reported a gross profit of DKK 520.0k in 2020.
How many employees does EmbryoTrans Biotech ApS have?
EmbryoTrans Biotech ApS employs 1 people as of the latest annual report.
Where is EmbryoTrans Biotech ApS headquartered?
EmbryoTrans Biotech ApS's registered address is Sommervænget 2.